TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Bioequivalence of oxycodone HCl ER tablets to OxyContin®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of oxycodone HCl ER tablets
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of clinical symptoms and signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Mass Index (BMI) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of lesions found
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Timed Up and Go Test (TUGT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: renal function deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Discounted life expectancy
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of diabetes-related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BDI score post-operatively
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progression to FTMH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to LH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight management counseling clinical teaching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage change in UACR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Blood Pressure (BP) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Satisfaction with preventive services delivery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HDL cholesterol improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective appearance of the scar
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Roll-off achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to completion of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total power output used for RF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain levels during packing removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lund-Kennedy score at postoperative 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 5 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Conversion rate of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success rate of electric cardioversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of atrial fibrillation relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak aerobic capacity (relative VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: submaximal power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: strength (vertical bench press, seated row, rickshaw press)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic or fatal intracranial hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary Tract Infection (UTI) rates within 6 weeks postoperatively
Endpoint domain: Adverse events/effects
Primary endpoint: mean number of prosthodontic maintenance events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to reline for overdentures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to remake of overdentures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete reversal of BO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stent-related discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention to-treat eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Per-protocol eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: long-term complication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: objective cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic Floor Impact Questionnaire (PFIQ-7) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of newborn hyperbilirubinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of newborn hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Changes in fasting plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart Rate Variability (SDNN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: overall blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of disease exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total annual cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fracture prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of HDLox
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportions of patients achieving serum UA target levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean reduction in central subfield thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean visual acuity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual desire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: New onset diabetes
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of trimethoprim/sulfamethoxazole-resistant Enterobacteriaceae
Endpoint domain: Adverse events/effects
Primary endpoint: Integron prevalence
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in the IIQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient global ratings of satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: blood glucose profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improved quality of life related to oral health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: LH and ACTH increments during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: T and cortisol increments during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: patient-days compatible with discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased antibiotic prescribing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of accessory muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mental test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HCV RNA negative rate at 24 weeks after treatment
Endpoint domain: Mortality/survival
Primary endpoint: life year in remission
Endpoint domain: Mortality/survival
Primary endpoint: quality-adjusted life year
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ASEPSIS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean reduction in blood pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure control (<140/90 mm Hg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Renal-sinus-fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial MLSI (IxA) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of exit-site infections
Endpoint domain: Adverse events/effects
Primary endpoint: Heart failure events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: absolute mean change in prednisolone dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IWQOL-Lite total score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 6-month prevalence of any violence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serious violent behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drinks per day at last visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective high while smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: excursion distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: office BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean CS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean DASH score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: digit-span test score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: risk of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: early outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory Disease Assessment Inventory (RACS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bacteriologic failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum 25OHD level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort level of women
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time required to catheterize
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Impairment produced by visual degradation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairing effects of alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resting EEG in the gamma range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: attenuation of MP-related effects in the delta and alpha range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peak Expiratory Flow (PEF) % predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of relapses after treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative VTE recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Major and clinically relevant non-major bleeding rates
Endpoint domain: Adverse events/effects
Primary endpoint: Malaria parasite prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Visceral fat volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visceral fat TBR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensory block adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complete motor or sensory loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Health service cost of microwave endometrial ablation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: reduction in anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: low-density lipoprotein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lipoprotein-associated phospholipase A2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GCS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: decreased pain during placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased pain during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased pain during removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EC50 of remifentanil TCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EC95 of remifentanil TCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect-site concentration for preventing cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: isometric quadriceps strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: isokinetic quadriceps strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: sustained remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Satisfaction with ANC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-confidence in psychosocial skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: knowledge of psychosocial medicine
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Complete response rates for patients with at least one risk factor for CINV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total costs for TB/HIV
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: P-HSR rate
Endpoint domain: Adverse events/effects
Primary endpoint: Severe P-HSR occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Side effects from corticosteroid use
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment effect moderation by age and psychiatric problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for cervical dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Concentrations of xanthophylls in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular pigment optical density (MPOD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 2-h plasma glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Twin pregnancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Duration of embryo transfer procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Achieved target blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Limitations in activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Muscle flexibility of the lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: α‐tocopherol AUCs0‐10 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: γ‐tocopherol AUCs0‐10 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FVC (Forced Vital Capacity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anastomotic leak rates
Endpoint domain: Adverse events/effects
Primary endpoint: IL-8 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of blue-yellow color deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative incidence of chlamydia at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: transformation of relationships with exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: rCBF enhancement in the contralateral motor and somatosensory cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mortality after endoscopic therapy
Endpoint domain: Mortality/survival
Primary endpoint: Recurrent bleeding after endoscopic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean daytime systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: protein/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bacteriologic cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of errors in dual-task vigilance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of a first CNS event
Endpoint domain: Adverse events/effects
Primary endpoint: Median efavirenz plasma concentration (MEPC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from recurrent atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful subclavian vein cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average access time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of attempts for cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGF binding protein-3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Walking speed and distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wall thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent contrast enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence rate of nose injury
Endpoint domain: Adverse events/effects
Primary endpoint: body image score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PPT in the TMJ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate (DAS28 <2.6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTX‐II excretion reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aspergillus antigen detection by ELISA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants free from bulimic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraprocedural bleeding rate
Endpoint domain: Adverse events/effects
Primary endpoint: HD5 mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfer to NICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: 7KC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7betaOH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death hazard ratio of p53-positive versus p53-negative patients
Endpoint domain: Mortality/survival
Primary endpoint: Tumor SUV of FMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T/N and T/W ratios of FMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion rates for advance directives
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response to palliative radiation therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes